JP6990702B2 - 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体 - Google Patents

皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体 Download PDF

Info

Publication number
JP6990702B2
JP6990702B2 JP2019525851A JP2019525851A JP6990702B2 JP 6990702 B2 JP6990702 B2 JP 6990702B2 JP 2019525851 A JP2019525851 A JP 2019525851A JP 2019525851 A JP2019525851 A JP 2019525851A JP 6990702 B2 JP6990702 B2 JP 6990702B2
Authority
JP
Japan
Prior art keywords
azetidine
difluorophenoxy
trifluorophenoxy
compound
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019525851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535715A (ja
JP2019535715A5 (enExample
Inventor
ソネション，クラス
ペッテション，フレドリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Integrative Research Laboratories Sweden AB
Original Assignee
Integrative Research Laboratories Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrative Research Laboratories Sweden AB filed Critical Integrative Research Laboratories Sweden AB
Publication of JP2019535715A publication Critical patent/JP2019535715A/ja
Publication of JP2019535715A5 publication Critical patent/JP2019535715A5/ja
Application granted granted Critical
Publication of JP6990702B2 publication Critical patent/JP6990702B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019525851A 2016-11-18 2017-11-17 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体 Active JP6990702B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16199545 2016-11-18
EP16199545.1 2016-11-18
PCT/EP2017/079666 WO2018091687A1 (en) 2016-11-18 2017-11-17 Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

Publications (3)

Publication Number Publication Date
JP2019535715A JP2019535715A (ja) 2019-12-12
JP2019535715A5 JP2019535715A5 (enExample) 2020-11-12
JP6990702B2 true JP6990702B2 (ja) 2022-01-13

Family

ID=57348567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019525851A Active JP6990702B2 (ja) 2016-11-18 2017-11-17 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体

Country Status (10)

Country Link
US (1) US10875829B1 (enExample)
EP (1) EP3541784B1 (enExample)
JP (1) JP6990702B2 (enExample)
CN (1) CN109963834B (enExample)
DK (1) DK3541784T5 (enExample)
ES (1) ES2962865T3 (enExample)
FI (1) FI3541784T3 (enExample)
PL (1) PL3541784T3 (enExample)
PT (1) PT3541784T (enExample)
WO (1) WO2018091687A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112198237B (zh) * 2020-05-28 2021-08-06 扬子江药业集团广州海瑞药业有限公司 一种盐酸奈康唑杂质检测控制分析方法
EP4739654A1 (en) 2023-07-06 2026-05-13 Integrative Research Laboratories Sweden AB Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof
WO2025008506A1 (en) 2023-07-06 2025-01-09 Integrative Research Laboratories Sweden Ab 3-(2,3-difluorophenoxy)azetidine, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of pathological apathy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509860A (ja) 2008-11-24 2012-04-26 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な３−フェニル−アゼチジン誘導体
JP2013519732A (ja) 2010-02-17 2013-05-30 アムジエン・インコーポレーテツド 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体
WO2016030310A1 (en) 2014-08-27 2016-03-03 F. Hoffmann-La Roche Ag Substituted azetidine derivatives as taar ligands
WO2016073420A1 (en) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted azetidinyl compounds as glyt1 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638939A2 (en) * 2003-06-24 2006-03-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
JP5716202B2 (ja) 2008-11-24 2015-05-13 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての３−フェニル−３−メトキシピロリジン誘導体
JP2012515760A (ja) 2009-01-20 2012-07-12 ファイザー・インク 置換ピラジノンアミド
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
EP2718295A1 (en) 2011-06-07 2014-04-16 Pfizer Inc Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
KR101273566B1 (ko) 2011-09-05 2013-06-11 한국과학기술연구원 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
CN104093720B (zh) * 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
EP3297987B1 (en) * 2015-05-20 2019-05-15 Integrative Research Laboratories Sweden AB Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
CN108026030B (zh) 2015-09-18 2020-10-09 正大天晴药业集团股份有限公司 一种氘代化合物的制备方法
TWI752098B (zh) * 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509860A (ja) 2008-11-24 2012-04-26 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な３−フェニル−アゼチジン誘導体
JP2013519732A (ja) 2010-02-17 2013-05-30 アムジエン・インコーポレーテツド 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体
WO2016030310A1 (en) 2014-08-27 2016-03-03 F. Hoffmann-La Roche Ag Substituted azetidine derivatives as taar ligands
WO2016073420A1 (en) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted azetidinyl compounds as glyt1 inhibitors

Also Published As

Publication number Publication date
JP2019535715A (ja) 2019-12-12
CN109963834B (zh) 2023-04-14
US10875829B1 (en) 2020-12-29
CN109963834A (zh) 2019-07-02
PL3541784T3 (pl) 2024-03-11
ES2962865T3 (es) 2024-03-21
WO2018091687A1 (en) 2018-05-24
PT3541784T (pt) 2023-11-22
EP3541784A1 (en) 2019-09-25
DK3541784T3 (en) 2023-10-23
DK3541784T5 (da) 2024-09-16
EP3541784B1 (en) 2023-09-13
FI3541784T3 (fi) 2023-10-02

Similar Documents

Publication Publication Date Title
NO338622B1 (no) 3-(heteroaryl-oksy)-2-alkyl-1-aza-bicykloalkylderivater som alfa-7-nAChR ligander for terapi av CNS-sykdommer
EP4144352A1 (en) 2-amino-5,5-dimethylhexanoic acid derivatives as sortilin modulators for use in the treatment of disease of the central nervous system
JP5716202B2 (ja) 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての３−フェニル−３−メトキシピロリジン誘導体
RS55304B1 (sr) Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije
KR20130091362A (ko) 정신병성 및 신경퇴행성 장애의 치료를 위한 ｎ-ａｃｈｒ의 콜린성 리간드로서의 (1-아자-비시클로[3.3.1]논-4-일)-[5-(1ｈ-인돌-5-일)-헤테로아릴]-아민
US20250042905A1 (en) Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis
US10875829B1 (en) Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
US10287247B2 (en) Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
TWI376373B (en) Crystalline base of a pharmaceutical compound
JP2023507180A (ja) Ｏｇａ阻害剤化合物
JP5621087B2 (ja) 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な３−フェニル−アゼチジン誘導体
HK1245251A1 (en) Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
JP2010509250A (ja) 新規な２−アミノ−ピリジン誘導体及びカリウムチャネルモジュレーターとしてのその使用
JP2010509249A (ja) 新規な４−アミノ−ピリジン誘導体及びカリウムチャネルモジュレーターとしてのその使用
WO2025199234A1 (en) Vmat2 inhibitors and methods of use
EP4711367A1 (en) Pyrazolopyrazine compound and method for preparing crystal form thereof
CN117820309A (zh) 一种哌嗪基-杂环化合物及其用途
WO2024184468A1 (en) Modulators of sortilin activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211025

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211206

R150 Certificate of patent or registration of utility model

Ref document number: 6990702

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250